Clinical Trial Update: GIOTRIF rPMS in Korean Patients With NSCLC

View source ↗

Summary

A completed clinical trial update for GIOTRIF rPMS in Korean patients with non-small cell lung carcinoma (NSCLC) has results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• GIOTRIF rPMS (giotrif rPMS)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Status: COMPLETED | Results posted: 2021-02-24